108 related articles for article (PubMed ID: 35321552)
1. Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer.
Kuhl V; Clegg W; Meek S; Lenz L; Flake DD; Ronan T; Kornilov M; Horsch D; Scheer M; Farber D; Zalaznick H; Cussenot O; Compérat E; Cancel-Tassin G; Wild PJ; Chun FK; Mandel P; Moinfar F; Cohen T; Delee S; Kronenwett R; Doedt J
Biomark Med; 2022 Apr; 16(6):449-459. PubMed ID: 35321552
[TBL] [Abstract][Full Text] [Related]
2. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic heterogeneity in multifocal prostate cancer.
Salami SS; Hovelson DH; Kaplan JB; Mathieu R; Udager AM; Curci NE; Lee M; Plouffe KR; de la Vega LL; Susani M; Rioux-Leclercq N; Spratt DE; Morgan TM; Davenport MS; Chinnaiyan AM; Cyrta J; Rubin MA; Shariat SF; Tomlins SA; Palapattu GS
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385730
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
5. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.
Knezevic D; Goddard AD; Natraj N; Cherbavaz DB; Clark-Langone KM; Snable J; Watson D; Falzarano SM; Magi-Galluzzi C; Klein EA; Quale C
BMC Genomics; 2013 Oct; 14():690. PubMed ID: 24103217
[TBL] [Abstract][Full Text] [Related]
6. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
[TBL] [Abstract][Full Text] [Related]
7. Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression.
Luca BA; Moulton V; Ellis C; Connell SP; Brewer DS; Cooper CS
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708551
[TBL] [Abstract][Full Text] [Related]
8. Health economic impact of a biopsy-based cell cycle gene expression assay in localized prostate cancer.
Gustavsen G; Taylor K; Cole D; Gullet L; Lewine N
Future Oncol; 2020 Dec; 16(36):3061-3074. PubMed ID: 32902306
[No Abstract] [Full Text] [Related]
9. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
Freedland SJ; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Gutin A; Sangale Z; Lanchbury JS; Salama JK; Stone S
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):848-53. PubMed ID: 23755923
[TBL] [Abstract][Full Text] [Related]
10. Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
Lehto TK; Stürenberg C; Malén A; Erickson AM; Koistinen H; Mills IG; Rannikko A; Mirtti T
Prostate; 2021 May; 81(7):368-376. PubMed ID: 33734461
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry.
Crawford ED; Scholz MC; Kar AJ; Fegan JE; Haregewoin A; Kaldate RR; Brawer MK
Curr Med Res Opin; 2014 Jun; 30(6):1025-31. PubMed ID: 24576172
[TBL] [Abstract][Full Text] [Related]
12. Operator dependent choice of prostate cancer biopsy has limited impact on a gene signature analysis for the highly expressed genes IGFBP3 and F3 in prostate cancer epithelial cells.
Peng Z; Andersson K; Lindholm J; Bodin I; Pramana S; Pawitan Y; Nistér M; Nilsson S; Li C
PLoS One; 2014; 9(10):e109610. PubMed ID: 25296164
[TBL] [Abstract][Full Text] [Related]
13. Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives.
Hiser WM; Sangiorgio V; Bollito E; Esnakula A; Feely M; Falzarano SM
Future Oncol; 2018 Dec; 14(29):3073-3083. PubMed ID: 30107751
[TBL] [Abstract][Full Text] [Related]
14. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
15. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.
Ross AE; D'Amico AV; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):1-6. PubMed ID: 26123120
[TBL] [Abstract][Full Text] [Related]
16. Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer.
Wibmer AG; Robertson NL; Hricak H; Zheng J; Capanu M; Stone S; Ehdaie B; Brawer MK; Vargas HA
Abdom Radiol (NY); 2019 Aug; 44(8):2864-2873. PubMed ID: 31030245
[TBL] [Abstract][Full Text] [Related]
17. Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort.
Rubicz R; Zhao S; April C; Wright JL; Kolb S; Coleman I; Lin DW; Nelson PS; Ostrander EA; Feng Z; Fan JB; Stanford JL
Prostate; 2015 Sep; 75(13):1354-62. PubMed ID: 25990700
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
Sommariva S; Tarricone R; Lazzeri M; Ricciardi W; Montorsi F
Eur Urol; 2016 Jan; 69(1):107-15. PubMed ID: 25481455
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer.
Shore N; Concepcion R; Saltzstein D; Lucia MS; van Breda A; Welbourn W; Lewine N; Gustavsen G; Pothier K; Brawer MK
Curr Med Res Opin; 2014 Apr; 30(4):547-53. PubMed ID: 24320750
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
[No Abstract] [Full Text] [Related]
[Next] [New Search]
